Categories: All postsCannabis

Charlotte’s Web is a market leader in cannabis CBD, says M Partners

M Partners analyst Damian Karp is bullish on US cannabis company Charlotte’s Web Holdings (Charlotte’s Web Holdings Stock Quote, Chart CSE:CWEB), saying the makers of CBD wellness products should be able to maintain its market-leading position as it expands both domestically and internationally.

In a research note to clients Monday, Karp reiterated his “Buy” rating and C$35.00 target for CWEB, which represents a projected return of 19 per cent at the time of publication.

M Partners began covering Charlotte’s Web back in November 2018, with CWEB’s share price jumping 111 per cent since then. Karp has now revised his valuation methodology from a production-driven model to a demand-driven model, and thus his estimates have changed.

“The new methodology more accurately reflects Charlotte’s Web’s operations as its products make their way into more retail channels in the US,” Karp says. “We expect to see more retail presence in the near future to add to the CVS Health Corporation partnership and shipments of its first product orders to three national retail, grocery and drug chains. We view these partnerships as transformative and significant drivers of future growth.”

Karp is expecting CWEB to generate fiscal 2019 revenue and EBITDA of $251.0 million and $70.6 million, respectively, and fiscal 2020 revenue and EBITDA of $528.2 million and $198.4 million, respectively. (All figures in US dollars unless noted otherwise.)

As for potential catalysts, the analyst points to further consumer packaged goods partnerships, new stock-keeping units and product formulations, expansion updates and a potential listing on either the TSX or a US exchange.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: cweb
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

7 hours ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

8 hours ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

8 hours ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

23 hours ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

1 day ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

1 day ago